Subscribe

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS)

CNY17.25 +0.39 (+2.31%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address No. 1, Lize East 2nd Road 100102
Beijing, CN
CEO Qian Zhao
Website dcpc.com
IPO 1997-05-22
ISIN CNE000000Q94

Explore sections of this company profile

Description

China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its affiliated companies, operates as a prominent pharmaceutical enterprise within the People's Republic of China. The company's diverse product range includes various types of infusion solutions, available in soft bags, plastic and glass bottles, as well as inner-sealed and blend polypropylene bags. Its manufacturing capabilities extend to numerous injectable products, such as levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, and sodium chloride injections, among others. Additionally, it supplies vital dialysate solutions for both peritoneal and hemodialysis. A substantial part of its portfolio is dedicated to addressing cardiovascular and cerebrovascular diseases, featuring medications like compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, and edaravone. Furthermore, China Resources Double-Crane offers treatments for endocrinological conditions and a selection of pediatric drugs, notably including pediatric compound amino acid injections. The company's offerings also encompass nutritional supplements, such as vitamins E and C, and a variety of anti-infective pharmaceuticals. Headquartered in Beijing, the People's Republic of China, China Resources Double-Crane Pharmaceutical Co.,Ltd. is an affiliate of Beijing Pharmaceutical Group Co., Ltd.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY17.25 +0.39 (+2.31%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
-0.04
Float Shares
398.95M
Free Float %
38.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.45% -1.24% -6.22% -9.02% -10.05% -8.47% -14.20% -9.95% +38.58% +37.33% +429.75%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
17.25
DCF (Unlevered) 110.59 +541.1%
DCF (Levered) 38.57 +123.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2024-11 Change
Strong Buy 5 0
Buy 5 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
4.20
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -1.9% Q1'26: -8.8% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +0.6% Q1'26: -4.1% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +8.4% Q1'26: +2.3% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +17.7% ★ Q1'26: +18.7% (vs Q1'25)
  • ✓
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +15.2% ★ Q1'26: +15.0% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.6% Q1'26: +1.1% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.42× ★ Q1'26: 0.81× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.00) × ERP
WACC = 94% × Ke + 6% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 110.59 Current price: 17.25
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
2 EPS Ana. 		Dec 2027
2 Rev. Ana.
2 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
5.14B
est: 4.71B (+9.2%)
5.49B
est: 5.83B (-5.8%)
6.42B
est: 6.02B (+6.6%)
8.23B
est: 7.89B (+4.3%)
9.38B
est: 9.63B (-2.6%)
8.50B
est: 8.60B (-1.1%)
9.11B
est: 9.63B (-5.4%)
9.63B
est: 10.03B (-4.0%)
11.31B
est: 10.31B (+9.7%)
11.21B
est: 11.90B (-5.8%)
11.00B
est: 11.62B (-5.3%)
11.59B
11.51B – 11.68B
-0.2% YoY
12.18B
12.04B – 12.32B
+5.1% YoY
12.77B
12.64B – 12.89B
+4.8% YoY
EBITDA
1.08B
est: 895.10M (+21.0%)
1.23B
est: 1.11B (+10.4%)
1.39B
est: 1.15B (+21.5%)
1.54B
est: 1.50B (+2.6%)
1.63B
est: 1.83B (-10.8%)
1.59B
est: 1.64B (-2.6%)
1.58B
est: 1.83B (-13.6%)
1.99B
est: 1.91B (+4.2%)
2.62B
est: 3.38B (-22.5%)
2.60B
est: 3.90B (-33.3%)
2.73B
est: 3.81B (-28.2%)
3.80B
3.77B – 3.82B
-0.2% YoY
3.99B
3.94B – 4.04B
+5.1% YoY
4.18B
4.14B – 4.22B
+4.8% YoY
EBIT
813.90M
est: 639.09M (+27.4%)
909.74M
est: 792.07M (+14.9%)
1.05B
est: 817.86M (+28.9%)
1.19B
est: 1.07B (+11.4%)
1.27B
est: 1.31B (-2.7%)
1.22B
est: 1.17B (+4.4%)
1.13B
est: 1.31B (-13.3%)
1.45B
est: 1.36B (+6.3%)
1.95B
est: 2.41B (-19.0%)
1.88B
est: 2.79B (-32.4%)
1.94B
est: 2.72B (-28.5%)
2.71B
2.69B – 2.73B
-0.2% YoY
2.85B
2.82B – 2.88B
+5.1% YoY
2.99B
2.96B – 3.02B
+4.8% YoY
Net Income
661.06M
est: 935.40M (-29.3%)
714.21M
est: 808.09M (-11.6%)
842.61M
est: 885.16M (-4.8%)
968.59M
est: 969.71M (-0.1%)
1.06B
est: 1.04B (+1.8%)
1.01B
est: 996.90M (+0.8%)
935.69M
est: 1.09B (-14.1%)
1.18B
est: 1.10B (+7.3%)
1.67B
est: 1.39B (+19.8%)
1.63B
est: 1.73B (-5.7%)
1.65B
est: 1.72B (-4.3%)
1.76B
1.74B – 1.77B
+2.1% YoY
1.87B
1.83B – 1.90B
+6.6% YoY
2.05B
2.01B – 2.06B
+9.5% YoY
SGA
1.79B
est: 1.79B (+0.2%)
1.93B
est: 2.22B (-12.9%)
2.38B
est: 2.29B (+3.9%)
3.76B
est: 3.00B (+25.4%)
4.33B
est: 3.66B (+18.5%)
3.74B
est: 3.27B (+14.5%)
3.50B
est: 3.66B (-4.4%)
3.47B
est: 3.81B (-8.8%)
3.93B
est: 3.44B (+14.3%)
4.12B
est: 3.97B (+3.7%)
2.30B
est: 3.88B (-40.6%)
3.87B
3.84B – 3.90B
-0.2% YoY
4.07B
4.02B – 4.11B
+5.1% YoY
4.26B
4.22B – 4.30B
+4.8% YoY
EPS
0.63
est: 0.91 (-30.8%)
0.68
est: 0.79 (-13.5%)
0.81
est: 0.86 (-6.0%)
0.93
est: 0.94 (-1.4%)
1.01
est: 1.01 (+0.1%)
0.96
est: 0.97 (-1.0%)
0.90
est: 1.06 (-15.1%)
1.14
est: 1.07 (+6.5%)
1.63
est: 1.36 (+19.8%)
1.58
est: 1.67 (-5.4%)
1.59
est: 1.67 (-4.5%)
1.70
1.68 – 1.71
+1.8% YoY
1.81
1.77 – 1.84
+6.5% YoY
1.97
1.95 – 1.99
+9.1% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-28 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-27 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-26 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-25 A 4/5 5/5 4/5 5/5 3/5 2/5 3/5
2026-05-22 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-05-21 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-05-20 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-05-19 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-05-18 A 4/5 5/5 4/5 5/5 3/5 3/5 3/5
2026-05-15 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-14 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-13 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-12 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-11 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-08 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-07 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-06 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-30 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-29 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-28 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-27 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-24 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-23 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-22 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-21 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-20 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-17 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-16 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
500.76M
OE per share TTM
0.49
Owner's Yield
2.88%
Maintenance CapEx ratio
41.85%
Maint CapEx / Avg PPE
34.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 32 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS 0.05% 19.4K 0.65%
2 Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR 0.01% 8.4K 0.15%
3 Franklin FTSE China ETF FLCH 0.01% 32.3K 0.19%
4 Franklin FTSE China UCITS ETF FLXC.L 0.01% 140.9K 0.19%
5 Dimensional - Emerging Markets High Profitability ETF DEHP 0.01% 24.8K 0.44%
6 Dimensional - Emerging Markets Value ETF DFEV 0.00% 95.7K 0.46%
7 Dimensional Emerging Markets Sustainability Core 1 ETF DFSE 0.00% 20.6K 0.44%
8 Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX 0.00% 19.6K 0.40%
9 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 241.5K 0.29%
10 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 211.5K 0.39%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
144.9K
Shares Outstanding
1.04B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Chao Man Vice President — male
Donghan Yao Vice President — female
Hekai Tan Vice President — male
Ju Liu Board Secretary & Vice President — male
Qian Zhao President & Director — male
Wen Hao Huang Chief Financial Officer — male
Ziqin Liu Vice President — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic